CN115644433A - Application of phenyl coumarone KGM composition in inhibiting formation of gastrointestinal pentostatin - Google Patents
Application of phenyl coumarone KGM composition in inhibiting formation of gastrointestinal pentostatin Download PDFInfo
- Publication number
- CN115644433A CN115644433A CN202211205446.9A CN202211205446A CN115644433A CN 115644433 A CN115644433 A CN 115644433A CN 202211205446 A CN202211205446 A CN 202211205446A CN 115644433 A CN115644433 A CN 115644433A
- Authority
- CN
- China
- Prior art keywords
- kgm
- phenyl
- composition
- coumaran
- pentostatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The application discloses application of phenyl coumaran KGM composition in inhibiting formation of gastrointestinal pentostatin, and the application finds that the effect of inhibiting formation of pentostatin in gastrointestinal tract can be remarkably improved after the phenyl coumaran and KGM are used in combination. Based on this discovery, phenylcoumaran KGM compositions have utility in inhibiting the formation of gastrointestinal pentosans. Furthermore, the phenyl coumaran KGM composition has an application in preparing health-care food or medicines for inhibiting formation of gastrointestinal pentosans. Furthermore, the phenyl coumaran KGM composition has the application of preparing health-care food or medicine for treating, delaying or improving the diseases related to the pentose. Compared with single phenyl coumaran or glucomannan, the phenyl coumaran KGM composition has more remarkable effect of inhibiting the formation of gastrointestinal tract pentostatin, and has potential application prospects in the fields of diabetes and other diseases.
Description
Technical Field
The application belongs to the field of health-care food or medicine, and particularly relates to an application of a phenyl coumaran KGM composition in inhibiting formation of gastrointestinal pentostatin.
Background
The Maillard reaction is one of the main reasons for the unique flavor and color of food during processing. Which produce various maillard reaction products, such as pentosans, by reaction between carbonyl compounds (e.g., reducing sugars) and amino compounds (e.g., amino acids, proteins, etc.). With the intake of processed food, the accumulation of pentosan in human body is caused, and chronic metabolic diseases, such as hyperlipemia, diabetes, etc., are caused, which seriously harm human health. Therefore, accumulation of pentosan in human body can be reduced by inhibiting the formation of pentosan, thereby reducing the risk of various chronic diseases.
The phenyl coumaran is lignin with a unique structure, contains a beta-5 chemical connecting bond, has strong biological activity, has important functions in the aspects of oxidation resistance, blood fat reduction, blood sugar reduction, virus resistance and the like, and has important application value in the aspects of food, biology, medicine and the like. Meanwhile, the methoxyl group of the guaiacyl provides a strong electron cloud field for a benzene ring structure, activates phenolic hydroxyl on the benzene ring, and the beta-5 and the alpha-O-4 form a ring structure, so that the electron cloud fields on the two benzene rings present a synergistic effect, have very strong antioxidant activity and can effectively inhibit the formation of free radicals. It is known that the generation of pentosan is closely related to the formation of free radicals, and electron cloud fields on two benzene rings are connected through beta-5 and alpha-O-4 rings to enable the phenol type phenyl coumarins to obviously inhibit the formation of the free radicals, so that the generation of pentosan is reduced, and the pentosan is expected to be widely applied to the preparation of health-care food or medicines for treating, delaying or improving diseases related to pentosan.
Glucomannan (KGM), belonging to soluble hemicellulose, is a high-quality product in the seventh human nutrient cellulose, is a high molecular compound formed by combining glucose and mannose by beta-1,4 glycosidic bonds, and is a high-quality soluble dietary fiber. KGM has the functions of cleaning intestinal tract, improving glucose tolerance, preventing obesity, improving cholesterol metabolism, etc., and can prevent excessive absorption of sugar, fat and cholesterol by human body. Further research and deep development and utilization of KGM have attracted much attention, and KGM is now being used in the fields of food, medicine, and the like.
Disclosure of Invention
The object of the present application is to provide the use of a composition of phenyl coumaran KGM for inhibiting the formation of gastrointestinal pentosans.
According to the application, the phenyl coumaran and KGM (glucomannan) have a synergistic effect of inhibiting the formation of pentostatin in gastrointestinal tracts, and after the phenyl coumaran and the KGM are used in combination, the effect of inhibiting the formation of pentostatin in gastrointestinal tracts can be obviously improved. Based on this finding, a combination of phenyl coumaric acid and KGM has utility in inhibiting the formation of gastrointestinal pentosans.
Furthermore, the phenyl coumaran KGM composition has an application in preparing health-care food or medicines for inhibiting formation of gastrointestinal pentosans.
Furthermore, the phenyl coumaran KGM composition has the application in preparing health-care food or medicines for treating, delaying or improving pentose related diseases; the diseases related to the pentostatin comprise diabetes, alzheimer disease, atherosclerosis and the like.
Preferably, the phenyl coumaran is phenyl coumaran with a phenol structure and at least comprises one guaiacyl structural unit, and the guaiacyl structural unit is connected in a ring form through a beta-5 bond and an alpha-O-4 bond.
In some embodiments, the phenyl coumaran is bis-guaiacyl type phenyl coumaran or mono-guaiacyl type phenyl coumaran.
In some embodiments, the glucomannan has a molecular weight of 70 to 200 ten thousand.
In some embodiments, the mass ratio of phenylcoumaran to KGM in the composition of phenylcoumaran KGM is (1-4): 1, preferably (2-3): 1.
A health food or medicine for inhibiting the formation of gastrointestinal pentostatin contains phenylcoumarine KGM composition.
A health food or medicine for treating, delaying or improving pentostatin related diseases contains phenylcoumarine KGM composition.
In some embodiments, the mass ratio of phenylcoumaran to KGM in the composition of phenylcoumaran KGM is (1-4): 1, preferably (2-3): 1.
The beneficial effects of this application are as follows:
the phenyl coumaran and KGM have synergistic effect of synergistic inhibition on the formation of pentostatin in gastrointestinal tracts, compared with the single phenyl coumaran or KGM, the phenyl coumaran KGM composition has more remarkable effect of inhibiting the formation of pentostatin in gastrointestinal tracts, and has potential application prospect in the fields of oxidation resistance, aging resistance, diabetes resistance, alzheimer disease resistance, atherosclerosis resistance and other diseases.
Drawings
FIG. 1 shows the inhibition of pentosan by bis-guaiacyl phenylcoumaran, KGM and combinations thereof in the gastrointestinal digestion stage of example 1 of the present application;
FIG. 2 is a graph of the inhibition of pentosan by bis-guaiacyl coumarins, KGM and combinations thereof in the gastrointestinal digestion stage of example 2 of the present application;
FIG. 3 is a graph showing the inhibition of pentosan by bis-guaiacyl phenylcoumaran, KGM and combinations thereof during the gastrointestinal digestion stage of example 3;
FIG. 4 is a graph of the inhibition of pentosan by guaiacyl-type phenicol, KGM and a combination of both during the gastrointestinal digestion stage, as described in example 4 of the present application;
in FIGS. 1-4, the different letters A-C and a-C indicate that the difference is statistically significant, A, B and C indicate that the same sample has significant difference in oral cavity, stomach and intestine, respectively, and P is less than 0.01; a. b and c respectively show that significant differences exist among different samples in the same digestion stage, and P is less than 0.05.
Detailed Description
The following examples are intended to further illustrate the present application but should not be construed as limiting the same. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
The solutions prepared in the following examples were all prepared using water as a solvent, if not specified. The phenyl coumarins used in the examples below are commercially available from Merck Sigma-Aldrich. The glucomannan used in the examples described below was obtained from konjac mannan, product number K861211, from Shanghai Michelin Biotech, inc.
Example 1
The specific steps of this example are as follows:
(1) 30mg of bis-guaiacyl type phenyl coumaran is dissolved in 98ml of water, and 2ml of methanol is added to prepare a phenyl coumaran solution with the concentration of 0.3 g/L. The chemical formula of the bis-guaiacyl type phenyl coumaran is as follows:
(2) 30mg of glucomannan is dissolved in 100ml of water to prepare a glucomannan solution with the concentration of 0.3 g/L.
(3) The phenyl coumaran solution and the glucomannan solution are mixed according to the volume ratio of 2:1, and then the mixed solution is obtained by adopting a 0.22 mu m microporous membrane for sterilization treatment.
(4) Preparing artificial saliva (SSF) stock solution according to the table 1, and respectively adding 10ml of phenyl coumaran solution, glucomannan solution and mixed solution into 80ml of SSF; adding 2ml CaCl into each artificial saliva 2 And 2ml of ultrapure water, adding 3ml of Bovine Serum Albumin (BSA) and 3ml of glyoxal (glyoxal, GO), establishing a bovine serum albumin-glyoxal model (marked as a BSA-GO model), and uniformly mixing to obtain an oral cavity group. Artificial saliva with ultrapure water added alone was used as a control.
Table 1 formulation of simulated digestive juice stock solution
(5) Preparing artificial gastric juice (SGF) stock solutions according to the table 1, respectively adding 20ml of the prepared artificial gastric juice (SGF) stock solutions into the oral cavity group solution in the step (4), adjusting the pH value to 4 by using HCl solution, and then adding 2ml of pepsin and 2ml of CaCl 2 Finally, 2ml of ultrapure water was added thereto, and digestion was carried out in a 37 ℃ incubator to obtain a gastric digestion group.
(6) Preparing artificial intestinal juice (SIF) stock solution according to the table 1, adding 20ml of the artificial intestinal juice stock solution into the stomach digestion group obtained in the step (5), and then adding 1ml of pancreatin, 2ml of fresh pig bile salt and 2ml of CaCl 2 And adjusting the pH value to be neutral by NaOH to inactivate enzyme. Adding 2ml of ultrapure water, placing in a constant-temperature oscillation box at 37 ℃ for digestion for 2h, boiling to inactivate enzyme after digestion, and using as an intestinal digestion group.
(7) The results of in vitro digestion simulation to determine the pentose inhibition rate of the sample in different stages of oral cavity, stomach and intestine are shown in figure 1, and the figure shows that the composition of the bis-guaiacyl type phenyl coumaran and the glucomannan has synergistic effect on inhibiting the pentose.
In the examples, the method for measuring the rate of pentose inhibition is as follows:
at an excitation wavelength lambda by means of a Hitachi F-4700 fluorescence spectrophotometer ex =379nm and emission wavelength lambda em Fluorescence intensity at =463nm, the pentose content at different stages of the sample and the control sample is measured, and the pentose inhibition ratio is calculated by the formula: pentamicin inhibition (%) = (1-A) Sample (II) /A Control ) X is 100%; wherein A is Sample (A) Denotes the pentose content of the sample, A Control Represents the pentose content of the control sample.
Example 2
The specific steps of this example are as follows:
(1) 30mg of bis-guaiacyl type phenyl coumaran is dissolved in 98ml of water, and 2ml of methanol is added to prepare a phenyl coumaran solution with the concentration of 0.3 g/L.
(2) 30mg of glucomannan is dissolved in 100ml of water to prepare a glucomannan solution with the concentration of 0.3 g/L.
(3) The phenyl coumaran solution and the glucomannan solution are mixed according to the volume ratio of 2.5.
(4) Preparing artificial saliva (SSF) stock solution according to table 1, adding 10ml of phenyl coumaran solution, glucomannan solution and mixed solution into 80ml of SSF, and adding 2ml of CaCl into each part of artificial saliva 2 And 2ml of ultrapure water. Adding 3ml Bovine Serum Albumin (BSA) and 3ml glyoxal (glyoxal, GO), establishing a bovine serum albumin-glyoxal model (recorded as a BSA-GO model), and uniformly mixing to obtain an oral group. Artificial saliva with ultrapure water added alone was used as a control.
(5) Preparing artificial gastric juice (SGF) stock solutions according to the table 1, respectively adding 20ml of the prepared artificial gastric juice (SGF) stock solutions into the oral cavity group solution in the step (4), adjusting the pH value to 4 by using HCl solution, and then adding 2ml of pepsin and 2ml of CaCl 2 Finally, 2ml of ultrapure water was added thereto, and digestion was carried out in a 37 ℃ constant temperature shaking chamber to obtain a gastric digestion group.
(6) Preparing artificial intestinal juice (SIF) stock solution according to the table 1, adding 20ml of the artificial intestinal juice stock solution into the stomach digestion group obtained in the step (5), and then adding 1ml of pancreatin, 2ml of fresh pig bile salt and 2ml of CaCl 2 And adjusting the pH value to be neutral by NaOH to inactivate enzyme. Adding 2ml of ultrapure water, placing in a constant-temperature oscillation box at 37 ℃ for digestion for 2h, boiling to inactivate enzyme after digestion, and using as an intestinal digestion group.
(7) The in vitro digestion simulation shows that the results of the determination of the pentose inhibition rate of the sample in different stages of oral cavity, stomach and intestine are shown in figure 2, and the synergistic effect of the bis-guaiacyl phenyl coumaran and the glucomannan composition on the inhibition of pentose can be seen in the figure. See example 1 for a specific assay for pentostatin inhibition.
Example 3
The specific steps of this example are as follows:
(1) 30mg of bis-guaiacyl type phenyl coumaran is dissolved in 98ml of water, and 2ml of methanol is added to prepare a phenyl coumaran solution with the concentration of 0.3 g/L.
(2) 30mg of glucomannan is dissolved in 100ml of water to prepare a glucomannan solution with the concentration of 0.3 g/L.
(3) The phenyl coumaran solution and the glucomannan solution are mixed according to the volume ratio of 3:1, and then the mixed solution is obtained by adopting a 0.22 mu m microporous membrane for sterilization treatment.
(4) Preparing artificial saliva (SSF) stock solution according to table 1, adding 10ml of phenyl coumaran solution, glucomannan solution and mixed solution into 80ml of SSF, and adding 2ml of CaCl into each part of artificial saliva 2 And 2ml of ultrapure water. Adding 3ml Bovine Serum Albumin (BSA) and 3ml glyoxal (glyoxal, GO), establishing a bovine serum albumin-glyoxal model (recorded as a BSA-GO model), and uniformly mixing to obtain an oral group. Artificial saliva with ultrapure water added alone was used as a control.
(5) Preparing artificial gastric juice (SGF) stock solutions according to the table 1, respectively adding 20ml of the prepared artificial gastric juice (SGF) stock solutions into the oral cavity group solution in the step (4), adjusting the pH value to 4 by using HCl solution, and then adding 2ml of pepsin and 2ml of CaCl 2 Finally, 2ml of ultrapure water was added thereto, and digestion was carried out in a 37 ℃ incubator to obtain a gastric digestion group.
(6) Preparing artificial intestinal juice (SIF) stock solution according to the table 1, adding 20ml of the artificial intestinal juice stock solution into the stomach digestion group obtained in the step (5), and then adding 1ml of pancreatin, 2ml of fresh pig bile salt and 2ml of CaCl 2 And adjusting the pH value to be neutral by using NaOH to inactivate the enzyme. Adding 2ml of ultrapure water, placing in a constant-temperature oscillation box at 37 ℃ for digestion for 2h, boiling to inactivate enzyme after digestion, and using as an intestinal digestion group.
(7) The results of in vitro digestion simulation to determine the pentose inhibition rate of the sample in different stages of oral cavity, stomach and intestine are shown in figure 3, and the figure shows that the double guaiacyl type phenyl coumaran and glucomannan composition produce synergistic effect on inhibiting pentose. See example 1 for a specific assay for pentostatin inhibition.
Example 4
The specific steps of this example are as follows:
(1) 30mg Shan Yuchuang Wood-based Phenylcoumarane is dissolved in 98ml water, and 2ml methanol is added to prepare a Phenylcoumarane solution with a concentration of 0.3 g/L. Shan Yuchuang Phenylcoumaran has the formula:
(2) 30mg of glucomannan is dissolved in 100ml of water to prepare a glucomannan solution with the concentration of 0.3 g/L.
(3) The phenyl coumaran solution and the glucomannan solution are mixed according to the volume ratio of 3:1, and then the mixed solution is obtained by adopting a 0.22 mu m microporous membrane for sterilization treatment.
(4) Preparing artificial saliva (SSF) stock solution according to table 1, adding 10ml of phenyl coumaran solution, glucomannan solution and mixed solution into 80ml of SSF, and adding 2ml of CaCl into each part of artificial saliva 2 And 2ml of ultrapure water. Adding 3ml Bovine Serum Albumin (BSA) and 3ml glyoxal (glyoxal, GO), establishing a bovine serum albumin-glyoxal model (recorded as a BSA-GO model), and uniformly mixing to obtain an oral group. Artificial saliva with ultrapure water added alone was used as a control.
(5) Preparing artificial gastric juice (SGF) stock solutions according to the table 1, respectively adding 20ml of the prepared artificial gastric juice (SGF) stock solutions into the oral cavity group solution in the step (4), adjusting the pH value to 4 by using HCl solution, and then adding 2ml of pepsin and 2ml of CaCl 2 Finally, 2ml of ultrapure water was added thereto, and digestion was carried out in a 37 ℃ incubator to obtain a gastric digestion group.
(6) Preparing artificial intestinal juice (SIF) stock solution according to the table 1, adding 20ml of the artificial intestinal juice stock solution into the stomach digestion group obtained in the step (5), and then adding 1ml of pancreatin, 2ml of fresh pig bile salt and 2ml of CaCl 2 And adjusting the pH value to be neutral by NaOH to inactivate enzyme. Adding 2ml of ultrapure water, placing in a constant-temperature oscillation box at 37 ℃ for digestion for 2h, boiling to inactivate enzyme after digestion, and using as an intestinal digestion group.
(7) The in vitro digestion simulation is carried out to determine the pentose inhibition rate of the sample in different stages of oral cavity, stomach and intestine, the result is shown in figure 4, and the single guaiacyl type phenyl coumaran and glucomannan composition can be seen in the figure to produce synergistic effect on inhibiting pentose. See example 1 for a specific assay for pentostatin inhibition.
Referring to fig. 1-4, the inhibition of pentostatin is shown for samples at different stages of gastrointestinal digestion, with the abscissa representing the digestion stage, including the oral, gastric, and intestinal stages, and the ordinate representing the inhibition of pentostatin. In the oral cavity stage, the inhibition rate of the sample on the pentosan is low; from the gastric stage, the sample has a significantly enhanced pentostatin inhibitory effect. In the stomach stage and the intestine stage, the phenyl coumaran and the glucomannan have the inhibition capacity on pentostatin, but the pentostatin inhibition rate of the composition is obviously superior to that of the phenyl coumaran and the glucomannan, which shows that the phenyl coumaran and the glucomannan composition generate a synergistic effect and can obviously improve the pentostatin resistance.
The foregoing description only represents the specific embodiments of the present application, and it should be noted that, for those skilled in the art, various changes and modifications can be made without departing from the technical concept of the present application, and these changes and modifications are all within the scope of the present application.
Claims (10)
1. Use of a composition of phenylcoumarine KGM for inhibiting the formation of gastrointestinal pentostatin.
2. Application of phenyl coumaran KGM composition in preparing health food or medicine for inhibiting formation of gastrointestinal pentostatin is provided.
3. The application of the composition of phenyl coumaric acid KGM in preparing health-care food or medicine for treating, delaying or improving the diseases related to pentostatin.
4. The use according to any one of claims 1 to 3, wherein the phenyl coumaran is phenyl coumaran having a phenolic structure and comprising at least one guaiacyl building block, the guaiacyl building blocks being linked together by a β -5 linkage and an α -O-4 linkage to form a ring.
5. The use of claim 4, wherein the phenyl coumaran is bis-guaiacyl type phenyl coumaran or mono-guaiacyl type phenyl coumaran.
6. The use as claimed in any one of claims 1 to 3, wherein the glucomannan has a molecular weight of from 70 to 200 ten thousand.
7. The use according to any one of claims 1 to 3, wherein the composition of phenyl coumaran and glucomannan has a mass ratio of phenyl coumaran to glucomannan of (1-4): 1.
8. A health food or medicine for inhibiting the formation of gastrointestinal pentostatin, characterized in that: composition containing phenylcoumaran KGM.
9. A health food or medicine for treating, delaying or improving pentose related diseases is characterized in that: composition containing phenylcoumaran KGM.
10. The health food or pharmaceutical product according to any one of claims 8 to 9, wherein: in the phenyl coumaran KGM composition, the mass ratio of phenyl coumaran to glucomannan is (1-4) to 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211205446.9A CN115644433A (en) | 2022-09-30 | 2022-09-30 | Application of phenyl coumarone KGM composition in inhibiting formation of gastrointestinal pentostatin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211205446.9A CN115644433A (en) | 2022-09-30 | 2022-09-30 | Application of phenyl coumarone KGM composition in inhibiting formation of gastrointestinal pentostatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115644433A true CN115644433A (en) | 2023-01-31 |
Family
ID=84985013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211205446.9A Pending CN115644433A (en) | 2022-09-30 | 2022-09-30 | Application of phenyl coumarone KGM composition in inhibiting formation of gastrointestinal pentostatin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115644433A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103053903A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of reducing food glycemic indexes |
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| CN105705037A (en) * | 2013-07-31 | 2016-06-22 | 株式会社明治 | Nutritional composition for inhibiting growth of tumor |
| CN114698844A (en) * | 2022-04-11 | 2022-07-05 | 湖北工业大学 | Application of chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin |
-
2022
- 2022-09-30 CN CN202211205446.9A patent/CN115644433A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103053903A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of reducing food glycemic indexes |
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| CN105705037A (en) * | 2013-07-31 | 2016-06-22 | 株式会社明治 | Nutritional composition for inhibiting growth of tumor |
| CN114698844A (en) * | 2022-04-11 | 2022-07-05 | 湖北工业大学 | Application of chitosan procyanidin composition in inhibiting formation of gastrointestinal pentostatin |
Non-Patent Citations (3)
| Title |
|---|
| 施成成: "木质素和木质素-碳水化合物复合体的肠道菌群体外生物转化研究", pages 34 * |
| 李金玲等: "银杏LCC 制备多孔生物载体及在人体肝细胞培养中的应用", 《林产化学与工业》 * |
| 石超群等: "植物细胞壁中甘露糖单元与木质素间化学键连接的研究", 《林产化学与工业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7923437B2 (en) | Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same | |
| US8222232B2 (en) | Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass | |
| Jung et al. | Effect of chitooligosaccharides on calcium bioavailability and bone strength in ovariectomized rats | |
| US5332803A (en) | Processes for the preparation of amylase inhibitor | |
| CN104877035B (en) | A kind of preparation method of the Blackfungus polyhexose with blood sugar reducing function | |
| WO2012013112A1 (en) | Method for extracting effective ingredients from sea cucumber by salting out | |
| CN110628859A (en) | Glycosylated oyster peptide and preparation method thereof | |
| CN110801024A (en) | Polysaccharide composite polypeptide for reducing blood sugar, blood fat and glycosylated hemoglobin and preparation method thereof | |
| CN115644433A (en) | Application of phenyl coumarone KGM composition in inhibiting formation of gastrointestinal pentostatin | |
| CN109535280A (en) | A kind of ascorbic acid chitosan oligosaccharide compound salt and its preparation method and application | |
| JP2005068112A (en) | Extract from grifola frondosa (a kind of mushroom) and glycoprotein and method for producing the same | |
| CN1463744A (en) | A health food possessing immunity regulating function and method for preparing the same | |
| JPH08291192A (en) | Lactonized oligosaccharide, its production and alpha amylase inhibitor | |
| CN115028750A (en) | Ascophyllum nodosum fucoidin and preparation method and application thereof | |
| CN114027510A (en) | Chlorella pyrenoidosa polysaccharide mixture, preparation method thereof and application of chlorella pyrenoidosa polysaccharide mixture as novel prebiotics | |
| CN113174411A (en) | Lactobacillus and rhodophyta fermentation supernatant with alpha-glucosidase inhibitory activity and application thereof | |
| JPS6359679B2 (en) | ||
| US20030104006A1 (en) | Hyaluronidase activity and allergenic cell activity inhibitor | |
| CN115708581A (en) | Use of lignin dehydrogenation polymers and xylan compositions for inhibiting the formation of pyridine derivatives in the gastrointestinal tract | |
| CN115057921B (en) | Gray sea horse oxidation-resistant fatigue-resistant active collagen peptide and large-scale preparation method | |
| CN113101406B (en) | Starch composition and application thereof in preparation of hemostatic material | |
| CN114350732B (en) | Egg white protein peptide with antioxidant and anti-inflammatory effects | |
| JP7071224B2 (en) | β-glucan inclusion substance and its manufacturing method | |
| JP2003226701A (en) | Method for dissolving chitosan | |
| CN115606799A (en) | Application of phenyl coumarone in inhibiting formation of gastrointestinal tract cross-linking hormone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |